Evidence map›Paper›PMID 40444754›Full record

ReviewInternational journal of dermatology2025

Optimization of Basic Emollient Therapy for the Management of Xerosis Cutis.

Matthias Augustin, Mélanie Brignone

Abstract readReview
In one paragraph

Review in International journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthias AugustinInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.ORCID https://orcid.org/0000-0002-4026-8728
Mélanie BrignoneMarket Access and Health Economics and Outcomes Research, Pierre Fabre, Boulogne-Billancourt, France.

Funding

Les Laboratories Pierre Fabre
6 · The paper itself

Abstract

Topical emollients are the mainstay of basic therapy for managing xerosis cutis (dry skin). In general, most emollient formulations are safe and effective for xerosis cutis and diseases associated with dry skin; however, several other factors can vary widely between products, influence patient adherence, and ultimately affect treatment success. This article reviews key practical and clinical considerations when prescribing emollients for xerosis cutis and discusses strategies to optimize treatment and clinical outcomes for these patients. Although the optimal quantity and frequency of emollient use depend on the extent and severity of skin dryness, frequent (i.e., up to several times daily) and liberal application (i.e., up to 600 g/week) are generally recommended. Lipid-rich ointments are indicated for very dry skin, while hydrophilic creams and lotions are suitable for less severe xerosis cutis; however, treatment decisions should also be guided by other factors (e.g., cosmetic acceptability and practicality) to ensure that patients can adhere to long-term emollient therapy. Strategies to promote shared decision-making and improve treatment adherence include patient education, allowing patients to trial a range of emollient products, regularly following-up with patients, and adjusting treatment to suit their preferences. Emollient therapy is a cost-effective strategy to manage patients with chronic dry skin conditions; however, access to basic, lower-cost formulations remains important to minimize the financial burden on patients. Overall, treatment effectiveness and clinical need should be balanced with individual patient preferences to ensure that the full benefits of emollient therapy for xerosis cutis are realized.

Indexed as

EmollientsSkin DiseasesAdministration, CutaneousHumansMedication AdherenceOintmentsPatient Education as TopicSeverity of Illness IndexSkin CreamEmollientsOintmentsadherencecost‐effectivenessdry skinemollientmoisturizerxerosis cutis

Identifiers

PMID40444754
PMCPMC12124103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.